Kymera Therapeutics (NASDAQ:KYMR) Stock Keeps "Buy" Rating at Truist Financial

Key Points

• Truist Financial reaffirmed its Buy rating on Kymera Therapeutics and raised its price target to $150 from $136, implying approximately 24% upside. Other analysts remain broadly positive, with the stock carrying a “Moderate Buy” consensus rating and a $137.92 average target.
• Kymera reported positive Phase 1 results for its oral IRF5 degrader KT-579, showing sustained target degradation, favorable biomarker changes and a favorable safety profile in healthy volunteers.
• The company’s latest quarter fell short of expectations: it reported a $1.32 per-share loss versus the $1.26 consensus estimate, while revenue of $1.35 million missed expectations of $3.28 million.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report)'s stock had its "buy" rating restated by analysts at Truist Financial in a note issued to investors on Friday, Benzinga reports. They currently have a $150.00 price objective on the stock, up from their previous price objective of $136.00. Truist Financial's price objective points to a potential upside of 24.07% from the company's previous close.

Other research analysts have also issued reports about the company. Barclays upped their price target on Kymera Therapeutics from $133.00 to $139.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Guggenheim raised their price target on Kymera Therapeutics from $135.00 to $170.00 and gave the company a "buy" rating in a report on Monday, August 31st. Raymond James Financial reissued an "outperform" rating on shares of Kymera Therapeutics in a research note on Thursday. Bank of America lifted their price target on shares of Kymera Therapeutics from $123.00 to $144.00 and gave the stock a "buy" rating in a research report on Monday, September 14th. Finally, Mizuho boosted their target price on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an "outperform" rating in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $137.92.

Kymera Therapeutics Stock Performance

KYMR traded down $1.70 during trading on Friday, reaching $120.90. The company had a trading volume of 375,810 shares, compared to its average volume of 746,932. The firm's 50-day simple moving average is $114.83 and its 200 day simple moving average is $96.08. The company has a market cap of $10.05 billion, a price-to-earnings ratio of -37.34 and a beta of 1.98. Kymera Therapeutics has a 12-month low of $55.66 and a 12-month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported ($1.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.06). Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The business had revenue of $1.35 million for the quarter, compared to analysts' expectations of $3.28 million. During the same quarter in the prior year, the firm posted ($0.94) EPS. The business's quarterly revenue was up .0% compared to the same quarter last year. On average, sell-side analysts expect that Kymera Therapeutics will post -3.85 EPS for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, insider Brian Adams sold 6,371 shares of the firm's stock in a transaction on Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the transaction, the insider owned 50,254 shares in the company, valued at $5,871,174.82. This trade represents a 11.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the transaction, the chief executive officer owned 666,568 shares of the company's stock, valued at approximately $75,855,438.40. This represents a 4.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 15.98% of the stock is owned by company insiders.

Institutional Trading of Kymera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KYMR. BlackRock Inc. acquired a new position in Kymera Therapeutics in the second quarter valued at approximately $635,067,000. Merck & Co. Inc. bought a new stake in Kymera Therapeutics in the second quarter valued at $88,544,161. Jennison Associates LLC raised its holdings in shares of Kymera Therapeutics by 2.5% during the first quarter. Jennison Associates LLC now owns 508,999 shares of the company's stock valued at $42,395,000 after purchasing an additional 12,334 shares during the period. Bank of America Corp DE bought a new position in shares of Kymera Therapeutics during the 2nd quarter worth about $43,378,000. Finally, Braidwell LP grew its stake in shares of Kymera Therapeutics by 12.0% in the 2nd quarter. Braidwell LP now owns 378,163 shares of the company's stock valued at $43,364,000 after buying an additional 40,604 shares during the period.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, an oral IRF5 degrader. The drug produced deep, sustained IRF5 degradation, robust changes in disease-relevant biomarkers and a favorable safety profile in healthy volunteers, strengthening the case for continued development in immunological diseases. Kymera Announces Q3 2026 Results and KT-579 Phase 1 Data
• Positive Sentiment: Truist Securities raised its price target on KYMR to $150 from $136 while maintaining a Buy rating, signaling increased confidence in Kymera’s pipeline and potential upside. Truist Raises Kymera Price Target
• Positive Sentiment: BTIG Research also increased its target to $139 from $134 and initiated or maintained a Buy rating, adding further analyst support for the shares.
• Neutral Sentiment: The company’s Q3 earnings call focused on the financial results and KT-579 development update. Investors are likely to look for additional guidance on clinical timelines, future trials and cash resources as Kymera advances its pipeline. Kymera Q3 2026 Earnings Call Transcript
• Negative Sentiment: Kymera reported a third-quarter loss of $1.32 per share, wider than the $1.26 analyst consensus, while revenue of $1.35 million fell short of the $3.28 million estimate. The company’s negative profitability metrics and widening net loss remain risks for investors in this clinical-stage biotech. Kymera Q3 2026 Financial Results

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell's natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company's research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.